REG - Mediclinic Intnl plc JPMorgan Chase & Co - Holding(s) in Company

JPMorgan Chase & CoAnnouncement

28/09/2022 16:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220928:nRSb0454Ba&default-theme=true

RNS Number : 0454B  Mediclinic International plc  28 September 2022

Mediclinic International plc

(Incorporated in England and Wales)

Company Number: 08338604

LSE Share Code: MDC

JSE Share Code: MEI

NSX Share Code: MEP

ISIN: GB00B8HX8Z88

LEI: 2138002S5BSBIZTD5I60

South African income tax number: 9432434182

('Mediclinic', the 'Company', or the 'Group')

 

28 September 2022

TR-1: Standard form for notification of major holdings

1. Issuer Details

ISIN

GB00B8HX8Z88

Issuer Name

MEDICLINIC INTERNATIONAL PLC

UK or Non-UK Issuer

UK

2. Reason for Notification

An acquisition or disposal of voting rights

3. Details of person subject to the notification obligation

Name

JPMorgan Chase & Co.

City of registered office (if applicable)

 

Country of registered office (if applicable)

US

4. Details of the shareholder

 Name                        City of registered office  Country of registered office
 J.P. Morgan Securities plc

5. Date on which the threshold was crossed or reached

26-Sep-2022

6. Date on which Issuer notified

28-Sep-2022

7. Total positions of person(s) subject to the notification obligation

                                                                            % of voting rights attached to shares (total of 8.A)  % of voting rights through financial instruments (total of 8.B 1 + 8.B 2)  Total of both in % (8.A + 8.B)  Total number of voting rights held in issuer
 Resulting situation on the date on which threshold was crossed or reached  3.271379                                              1.756331                                                                   5.027710                        37066786
 Position of previous notification (if applicable)                          Below minimum threshold                               Below minimum threshold                                                    Below minimum threshold

8. Notified details of the resulting situation on the date on which the
threshold was crossed or reached

8A. Voting rights attached to shares

 Class/Type of shares ISIN code(if possible)  Number of direct voting rights (DTR5.1)  Number of indirect voting rights (DTR5.2.1)  % of direct voting rights (DTR5.1)  % of indirect voting rights (DTR5.2.1)
 GB00B8HX8Z88                                                                          24118142                                                                         3.271379
 Sub Total 8.A                                24118142                                                                              3.271379%

8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))

 Type of financial instrument  Expiration date  Exercise/conversion period  Number of voting rights that may be acquired if the instrument is  % of voting rights
                                                                            exercised/converted

 Sub Total 8.B1

8B2. Financial Instruments with similar economic effect according to
(DTR5.3.1R.(1) (b))

 Type of financial instrument  Expiration date  Exercise/conversion period  Physical or cash settlement  Number of voting rights  % of voting rights
 Cash-settled Equity Swap      26/10/2022       26/10/2022                  Cash                         5474521                  0.742564
 Cash-settled Equity Swap      28/10/2022       28/10/2022                  Cash                         3241439                  0.439669
 Cash-settled Equity Swap      23/11/2022       23/11/2022                  Cash                         58635                    0.007953
 Cash-settled Equity Swap      01/02/2023       01/02/2023                  Cash                         16152                    0.002190
 Cash-settled Equity Swap      04/07/2023       04/07/2023                  Cash                         4119024                  0.558694
 Cash-settled Equity Swap      12/07/2023       12/07/2023                  Cash                         5065                     0.000682
 Cash-settled Equity Swap      09/08/2023       09/08/2023                  Cash                         759                      0.000102
 Cash-settled Equity Swap      18/08/2023       18/08/2023                  Cash                         145                      0.000019
 Cash-settled Equity Swap      22/08/2023       22/08/2023                  Cash                         598                      0.000081
 Cash-settled Equity Swap      06/09/2023       06/09/2023                  Cash                         8277                     0.001122
 Cash-settled Equity Swap      21/09/2023       21/09/2023                  Cash                         1588                     0.000215
 Cash-settled Equity Swap      03/10/2023       03/10/2023                  Cash                         5518                     0.000747
 Cash-settled Equity Swap      19/10/2023       19/10/2023                  Cash                         3768                     0.000511
 Cash-settled Equity Swap      27/10/2023       27/10/2023                  Cash                         647                      0.000087
 Cash-settled Equity Swap      12/02/2024       12/02/2024                  Cash                         11910                    0.001615
 Cash-settled Equity Swap      06/07/2027       06/07/2027                  Cash                         309                      0.000041
 Cash-settled Equity Swap      03/08/2027       03/08/2027                  Cash                         289                      0.000039
 Sub Total 8.B2                                                                                          12948644                 1.756331%

9. Information in relation to the person subject to the notification
obligation

2. Full chain of controlled undertakings through which the voting rights
and/or the financial instruments are effectively held starting with the
ultimate controlling natural person or legal entities (please add additional
rows as necessary)

 Ultimate controlling person  Name of controlled undertaking                         % of voting rights if it equals or is higher than the notifiable threshold  % of voting rights through financial instruments if it equals or is higher  Total of both if it equals or is higher than the notifiable threshold
                                                                                                                                                                 than the notifiable threshold
 JPMorgan Chase & Co.         J.P. Morgan Securities plc                                                                                                                                                                                     4.383003%
 JPMorgan Chase & Co.         JPMorgan Chase Bank, National Association
 JPMorgan Chase & Co.         J.P. Morgan Equities South Africa Proprietary Limited
 JPMorgan Chase & Co.         J.P. Morgan Securities LLC

10. In case of proxy voting

Name of the proxy holder

 

The number and % of voting rights held

 

The date until which the voting rights will be held

 

11. Additional Information

Chain of controlled undertakings:

JPMorgan Chase & Co.

JPMorgan Chase Bank, National Association (100%)

J.P. Morgan International Finance Limited (100%)

J.P. Morgan Capital Holdings Limited (100%)

J.P. Morgan Securities plc (100%)

JPMorgan Chase & Co.

JPMorgan Chase Bank, National Association (100%)

JPMorgan Chase & Co.

JPMorgan Chase Bank, National Association (100%)

J.P. Morgan International Finance Limited (100%)

J.P. Morgan Capital Holdings Limited (100%)

J.P. Morgan Equities South Africa Proprietary Limited (100%)

JPMorgan Chase & Co.

JPMorgan Chase Holdings LLC (100%)

J.P. Morgan Broker-Dealer Holdings Inc. (100%)

J.P. Morgan Securities LLC (100%)

12. Date of Completion

28-Sep-2022

13. Place Of Completion

London

 

 

About Mediclinic International plc

 

Mediclinic is a diversified international private healthcare services group,
established in South Africa in 1983, with divisions in Switzerland, Southern
Africa (South Africa and Namibia) and the Middle East.

 

The Group's core purpose is to enhance the quality of life.

 

Its vision is to be the partner of choice that people trust for all their
healthcare needs.

 

Mediclinic is focused on providing specialist-orientated, multi-disciplinary
services across the continuum of care in such a way that the Group will be
regarded as the most respected and trusted provider of healthcare services by
patients, medical practitioners, funders and regulators of healthcare in each
of its markets.

 

At 30 June 2022, Mediclinic comprised 74 hospitals, five subacute hospitals,
two mental health facilities, 20 day case clinics and 23 outpatient clinics.
The Swiss operations included 17 hospitals and four day case clinics with
around 1 900 inpatient beds; Southern Africa operations included 50 hospitals
(three of which in Namibia), five subacute hospitals, two mental health
facilities and 14 day case clinics (four of which operated by Intercare)
across South Africa, and around 8 650 inpatient beds; and the Middle East
operated seven hospitals, two day case clinics and 23 outpatient clinics with
around 1 000 inpatient beds in the UAE. In addition, under management contract
the Middle East will open a 200-bed hospital in the Kingdom of Saudi Arabia in
2023.

 

The Company's primary listing is on the London Stock Exchange ("LSE") in the
United Kingdom, with secondary listings on the JSE in South Africa and the
Namibian Stock Exchange in Namibia.

 

Mediclinic also holds a 29.7% interest in Spire Healthcare Group plc, a
leading private healthcare group based in the United Kingdom and listed on the
LSE.

 

For further information, please contact:

 

Company Secretary, Link Company Matters Limited

Caroline Emmet

+44 (0)333 300 1930

 

Investor Relations

James Arnold, Head of Investor Relations

ir@mediclinic.com

+44 (0)20 3786 8181

 

Media queries

FTI Consulting

Ben Atwell/Ciara Martin - United Kingdom

+44 (0)20 3727 1000

Sherryn Schooling - South Africa

+27 (0)21 487 9000

 

Registered address: 6(th) Floor, 65 Gresham Street, London, EC2V 7NQ, United
Kingdom

Website: www.mediclinic.com

Corporate broker (United Kingdom): Morgan Stanley & Co International plc
and UBS Investment Bank

JSE sponsor (South Africa): Rand Merchant Bank (A division of FirstRand Bank
Limited)

NSX sponsor (Namibia): Simonis Storm Securities (Pty) Ltd

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  HOLUWASRUNUKUAR